The company made good progress in 2016 despite the continued weakness in the UK market. Whilst overall sales were broadly flat at £6.32m, gross margins improved from 63% to 68%, reflecting a richer sales mix, FX benefits and manufacturing improvements. Coupled with reduced costs, this left the reported operating loss down 29% to £2.38m, (Arden forecast: £2.75m) and the loss before tax down 30% to £2.52m (2015: £3.60m). Cash held at the year-end was £0.6m an
27 Apr 2017
Finals – Improvement in sales trends and gross margins
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Finals – Improvement in sales trends and gross margins
Deltex Medical Group plc (DEMG:LON) | 0.1 0 0.0% | Mkt Cap: 2.37m
- Published:
27 Apr 2017 -
Author:
Chris Thomas -
Pages:
3
The company made good progress in 2016 despite the continued weakness in the UK market. Whilst overall sales were broadly flat at £6.32m, gross margins improved from 63% to 68%, reflecting a richer sales mix, FX benefits and manufacturing improvements. Coupled with reduced costs, this left the reported operating loss down 29% to £2.38m, (Arden forecast: £2.75m) and the loss before tax down 30% to £2.52m (2015: £3.60m). Cash held at the year-end was £0.6m an